Piragliatin

Drug Profile

Piragliatin

Alternative Names: GK Activator (2); GK2; R1440; RO4389620

Latest Information Update: 18 Sep 2008

Price : $50

At a glance

  • Originator Roche
  • Class Antihyperglycaemics; Benzeneacetamides; Pyrazines; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 11 Sep 2008 Efficacy data from a phase II trial in Type 2 diabetes presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD-2008)
  • 11 Sep 2008 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Type 2 diabetes mellitus presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD-2008)
  • 23 Jul 2007 Discontinued - Phase-II for Type-2 diabetes mellitus in World (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top